Veracyte earnings were $114.5M for the trailing 12 months ending Jun 30, 2026, with 311.4% growth year over year. The latest VCYT earnings report on Jun 30, 2026 announced Q2 2026 earnings of $25.5M, down 11.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VCYT reported annual earnings of $66.4M, with 174.9% growth. The next VCYT earnings date is Nov 3, 2026.
VCYT past earnings growth
How has VCYT's earnings growth performed historically?
On VCYT's earnings call on Jul 30, 2026, Veracyte (NASDAQ: VCYT) reported Q2 2026 earnings per share (EPS) of $0.32, up 3,300% year over year. Total VCYT earnings for the quarter were $25.49 million. In the same quarter last year, Veracyte's earnings per share (EPS) was -$0.01.
The next VCYT earnings date is Nov 3, 2026. Add VCYT to your watchlist to be reminded of Veracyte's next earnings date.
Is Veracyte profitable or losing money?
As of the last Veracyte earnings report, Veracyte is currently profitable. Veracyte's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $114.48 million, a 334.72% increase year over year.
What was VCYT's earnings growth in the past year?
As of Veracyte's earnings date in Jul 30, 2026, Veracyte's earnings has grown 311.43% year over year. This is 293.16 percentage points higher than the US Biotechnology industry earnings growth rate of 18.27%. VCYT earnings in the past year totalled $114.48 million.
What are Veracyte's earnings expectations?
The current EPS estimate for Veracyte's earnings report in Nov 3, 2026 is $0.28.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.